$9.9499
Insights on 89bio Inc
In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 58.0%
In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 83.4%
2.51%
Downside
Day's Volatility :5.28%
Upside
2.84%
33.87%
Downside
52 Weeks Volatility :71.3%
Upside
56.61%
Period | 89bio Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -42.99% | 0.3% | 0.0% |
6 Months | -51.3% | 1.7% | 0.0% |
1 Year | 24.97% | -4.0% | -2.4% |
3 Years | -62.72% | 17.2% | -6.5% |
Market Capitalization | 686.0M |
Book Value | $5.42 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.8 |
Wall Street Target Price | 32.44 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.61% |
Return On Equity TTM | -44.97% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -135.3M |
Diluted Eps TTM | -1.8 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.1 |
EPS Estimate Next Year | -2.56 |
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Next Quarter | -0.54 |
What analysts predicted
Upside of 226.03%
Sell
Neutral
Buy
89bio Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() 89bio Inc | 20.14% | -51.3% | 24.97% | -62.72% | -52.12% |
![]() Moderna, Inc. | 8.62% | -38.31% | -54.89% | -50.93% | 320.86% |
![]() Regeneron Pharmaceuticals, Inc. | -1.38% | 9.73% | 9.82% | 65.7% | 115.07% |
![]() Novo Nordisk A/s | -1.43% | 23.95% | 58.41% | 192.13% | 336.59% |
![]() Seagen, Inc. | 0.74% | 10.42% | 83.05% | 20.41% | 247.89% |
![]() Vertex Pharmaceuticals Incorporated | -8.19% | 7.19% | 13.58% | 55.97% | 97.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() 89bio Inc | NA | NA | NA | -2.1 | -0.45 | -0.26 | 0.0 | 5.42 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() 89bio Inc | Buy | $686.0M | -52.12% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $30.4B | 320.86% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 115.07% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 336.59% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 247.89% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 97.18% | 26.38 | 35.94% |
RA Capital Management, LLC
BlackRock Inc
State Street Corporation
HHG PLC
Vanguard Group Inc
Suvretta Capital Management, LLC
89bio Inc’s price-to-earnings ratio stands at None
Read More89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
Organization | 89bio Inc |
Employees | 45 |
CEO | Mr. Rohan Palekar |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$9.95
-0.1%
Advisorshares Alpha Dna Equity Sentiment Etf
$9.95
-0.1%
Falcon's Beyond Global Inc
$9.95
-0.1%
Jaguar Global Growth Corporation I
$9.95
-0.1%
Missfresh Ltd
$9.95
-0.1%
Shuaa Partners Acquisition Corp I
$9.95
-0.1%
Rose Hill Acquisition Corp
$9.95
-0.1%
Partners Bancorp
$9.95
-0.1%
Mercantile Bank Corp
$9.95
-0.1%